Antibody Drug Conjugates
At KCAS Bio, we leverage our bioanalytical expertise to support the development of next-generation ADCs, providing comprehensive services that ensure the efficacy and safety of these innovative treatments.
Advancing Antibody–Drug Conjugates: Precision Bioanalytical Services for Every Development Stage
KCAS Bio supports the development and characterization of Antibody–Drug Conjugates (ADCs) by providing comprehensive bioanalytical services. This includes customized solutions based on our LBA and Hybrid LC-MS/MS expertise, ensuring precise evaluation of ADC quantitation to assess efficacy, stability, and safety across preclinical and clinical development stages.
Antibody Drug Conjugate Technologies
KCAS Bio offers a range of advanced technologies to support ADC development including:
Bioanalytical Expertise:
Advanced platforms for quantifying total antibody and intact ADCs, evaluating payload release and quantifying drug-to-antibody ratios (DAR).
Mass Spectrometry:
LC-MS/MS methods for accurate and precise quantitation of payloads, total antibody and ADCs.
Ligand-Binding Assays:
Customized immunoassays to assess immunogenicity and quantitation of total antibody and ADCs.
Regulatory-Ready Solutions:
Compliance with GLP/GCP for submission-ready data packages.
ADC technologies include:
LC-MS
Hybrid LC-MS/MS
LBA (ELISA, MSD)
KCAS Bio conducts a variety of specialized tests to support the development and evaluation of Antibody–Drug Conjugates (ADCs). These include:
- Payload Analysis: Quantitation and characterization of the small molecule cytotoxic payload, including its release profile.
- Intact ADC Analysis: Assessment of the stability and integrity of the ADC in biological matrices.
- Pharmacokinetics (PK): Delivery of data for modeling the pharmacokinetics of the ADC in test subjects. Non-compartmental PK analysis to determine the ADC’s distribution, metabolism, and elimination profiles.
- Immunogenicity Testing: Detection of anti-drug antibodies (ADAs) to assess immune response risks.
- Stability Testing: Evaluation of ADC stability under various storage and physiological conditions.
- Drug-to-Antibody Ratio (DAR) Analysis: Precise measurement of the average number of payload molecules conjugated to each antibody.
Let KCAS Bio accelerate your ADC program
Our team of experts provides comprehensive bioanalytical and development solutions tailored to meet your unique needs. Specializing in Antibody-Drug Conjugates (ADCs) and other complex therapeutics, we offer a wide range of specialized services to support every stage of your development journey, delivering precise and reliable results.
Our people
Related services
Resources & Insights
Blogs
Anyone who has been following KCAS for any amount of time has likely heard us discuss the advantages of Hybrid LC-MS/MS for the bioanalysis of large molecules. As pioneers in the technology for many years, KCAS has become a strong proponent of working with our customers to demonstrate the quality…
Webinars
As the pharmaceutical industry continues to evolve, so does the technology behind drug development. One of the most groundbreaking advancements in bioanalysis is Hybrid LC-MS/MS technology, which is rapidly becoming the new standard for analyzing Antibody Drug Conjugates (ADCs). KCAS Bio is proud to be at the forefront of this…
Podcasts
In episode 84 of “The Weekly Bioanalysis”, our special guest, Bryan Parmentier, joins Dom and John to discuss his background and current role at KCAS Bio, offering insights into the field of small molecule method development. He delves into the typical challenges encountered when working with LC-MS analytes, and how…
Agile, responsive and easy to work with
We prepare and adapt our services based on a deep understanding of your drug development ambitions and wider business objectives.